Clareo Health | Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy
Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
St Vincent's Hospital, Sydney
With
Clarity Pharmaceuticals Ltd
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male patients aged 18 or above
Ability to provide informed consent documentation indicating that they understand the purpose of, and procedures required for the study, and are willing to participate in the study.
Prior radical prostatectomy for confirmed adenocarcinoma on histopathology.
Rising PSA (0.20 - 0.75 ng/mL) following radical prostatectomy with no prior salvage radiotherapy.
68Ga PSMA-11 PET/CT within the last 4 weeks for prostate cancer biochemical recurrence.
You may not be if
Prior, or contraindication to, salvage radiotherapy for biochemically recurrent prostate cancer.
History of current active malignancy as per investigator discretion other than prostate cancer.
Known or expected hypersensitivity to 64Cu-SAR-bisPSMA
Systemic therapy for metastatic prostate cancer including androgen deprivation therapy.
